Last reviewed · How we verify
olmesartan medoxomil + hydrochlorothiazide, if necessary
olmesartan medoxomil + hydrochlorothiazide, if necessary is a Angiotensin II receptor blocker + thiazide diuretic combination Small molecule drug developed by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. It is currently FDA-approved for Hypertension (essential hypertension).
Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption.
Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption. Used for Hypertension (essential hypertension).
At a glance
| Generic name | olmesartan medoxomil + hydrochlorothiazide, if necessary |
|---|---|
| Sponsor | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company |
| Drug class | Angiotensin II receptor blocker + thiazide diuretic combination |
| Target | AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing blood volume and peripheral vascular resistance. The combination provides complementary antihypertensive effects.
Approved indications
- Hypertension (essential hypertension)
Common side effects
- Dizziness
- Fatigue
- Hyperuricemia
- Hypokalemia
- Headache
- Cough
- Hyperglycemia
Key clinical trials
- Isolated Systolic Hypertension in the Elderly and Very Elderly (PHASE3)
- A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure (PHASE4)
- Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure (PHASE4)
- A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension (PHASE4)
- An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes (PHASE4)
- Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension (PHASE4)
- Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension (PHASE4)
- Vascular Improvement With Olmesartan Medoxomil Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- olmesartan medoxomil + hydrochlorothiazide, if necessary CI brief — competitive landscape report
- olmesartan medoxomil + hydrochlorothiazide, if necessary updates RSS · CI watch RSS
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company portfolio CI
Frequently asked questions about olmesartan medoxomil + hydrochlorothiazide, if necessary
What is olmesartan medoxomil + hydrochlorothiazide, if necessary?
How does olmesartan medoxomil + hydrochlorothiazide, if necessary work?
What is olmesartan medoxomil + hydrochlorothiazide, if necessary used for?
Who makes olmesartan medoxomil + hydrochlorothiazide, if necessary?
What drug class is olmesartan medoxomil + hydrochlorothiazide, if necessary in?
What development phase is olmesartan medoxomil + hydrochlorothiazide, if necessary in?
What are the side effects of olmesartan medoxomil + hydrochlorothiazide, if necessary?
What does olmesartan medoxomil + hydrochlorothiazide, if necessary target?
Related
- Drug class: All Angiotensin II receptor blocker + thiazide diuretic combination drugs
- Target: All drugs targeting AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
- Manufacturer: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension (essential hypertension)
- Compare: olmesartan medoxomil + hydrochlorothiazide, if necessary vs similar drugs
- Pricing: olmesartan medoxomil + hydrochlorothiazide, if necessary cost, discount & access